Related references
Note: Only part of the references are listed.Validation of the Boston University staging system in AL amyloidosis
Ross Tomlinson et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2019)
Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis
Brian Lilleness et al.
BLOOD (2019)
Systemic immunoglobulin light chain amyloidosis
Giampaolo Merlini et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2013)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2010)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
G Palladini et al.
CIRCULATION (2003)
Share Paper
